|Awarded On||November 16, 2016|
|Title||BBB-penetrating redox-responsive smart drugs and exploiting the MGMT-driven S-phase checkpoint for chemotherapy of childhood brain cancers|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||Texas Tech University Health Sciences Center|
|Principal Investigator/Program Director||Kalkunte S Srivenugopal|
|Cancer Sites||Brain and Other Nervous System|
Each year, about 4,300 children are diagnosed with brain tumors in the United States. Childhood brain cancers are deadly and rank as number two killer among pediatric patients. The last 20 years have seen some marked improvements in the survival of patients with mild medulloblastomas, however, the outlook for malignant gliomas, high-risk medulloblastomas, and diffuse brainstem gliomas in children has changed very little. Every brain tumor patient goes through chemotherapy using alkylating agents. However, the treatment fails because, these tumors have multiple genetic abnormalities, and malignant cells can escape the cytotoxic effects of drugs and develop resistance. Chemo-drugs for brain ...